Essential role of transient receptor potential vanilloid type 1 in evodiamine-mediated protection against atherosclerosis

Acta Physiologica

Volumn 207, Issue 2, 2013, Pages 299-307

  Wei, J ^a   Ching, L C ^b   Zhao, J F ^b   Shyue, S K ^c   Lee, H F ^a,b   Kou, Y R ^b   Lee, T S ^b  

^a CHENG HSIN GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

Author keywords

Atherosclerosis; Cholesterol metabolism; Evodiamine; Inflammation; Transient receptor potential vanilloid type 1

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER G5; ABC TRANSPORTER G8; APOLIPOPROTEIN E; CHEMOKINE; CHOLESTEROL; CHOLESTEROL 7ALPHA MONOOXYGENASE; CYTOKINE; EOSIN; EVODIAMINE; HEMATOXYLIN; LOW DENSITY LIPOPROTEIN RECEPTOR; OXYGENASE; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FATTY LIVER; FEMALE; GENE DELETION; HEART PROTECTION; HISTOPATHOLOGY; HYPERLIPIDEMIA; INFLAMMATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; WESTERN BLOTTING;

ANIMALS; APOLIPOPROTEINS E; BLOTTING, WESTERN; CORONARY ARTERY DISEASE; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FATTY LIVER; HYPERLIPIDEMIAS; MALE; MICE; MICE, KNOCKOUT; QUINAZOLINES; TRPV CATION CHANNELS;

EID: 84872187434     PISSN: 17481708     EISSN: 17481716     Source Type: Journal    
DOI: 10.1111/apha.12005     Document Type: Article

References (58)

1. Angulo, P. 2002. Nonalcoholic fatty liver disease. N Engl J Med 346, 1221-1231.
2. Bak, E.J., Park, H.G., Kim, J.M., Kim, J.M., Yoo, Y.J. and Cha, J.H. 2010. Inhibitory effect of evodiamine alone and in combination with rosiglitazone on in vitro adipocyte differentiation and in vivo obesity related to diabetes. Int J Obes (Lond) 34, 250-260.
3. Baylie, R.L. and Brayden, J.E. 2011. TRPV channels and vascular function. Acta Physiol (Oxf) 203, 99-116.
4. Beech, D.J. 2012. Integration of transient receptor potential canonical channels with lipids. Acta Physiol (Oxf) 204, 227-237.
5. Birder, L.A., Wolf-Johnston, A.S., Sun, Y. and Chai, T.C. 2012. Alteration in TRPV1 and Muscarinic (M3) receptor expression and function in idiopathic overactive bladder urothelial cells. Acta Physiol (Oxf) doi: 10.1111/j.1748-1716.2012.02462.x.
6. Brown, B.G., Zambon, A., Poulin, D., Rocha, A., Maher, V.M., Davis, J.W., Albers, J.J. and Brunzell, J.D. 1998. Use of niacin, statins, and resins in patients with combined hyperlipidemia. Am J Cardiol 81, 52B-59B.
7. Ching, L.C., Kou, Y.R., Shyue, S.K., Su, K.H., Wei, J., Cheng, L.C., Yu, Y.B., Pan, C.C. and Lee, T.S. 2011. Molecular mechanisms of activation of endothelial nitric oxide synthase mediated by transient receptor potential vanilloid type 1. Cardiovasc Res 91, 492-501.
8. Ching, L.C., Chen, C.Y., Su, K.H., Hou, H.H., Shyue, S.K., Kou, Y.R. and Lee, T.S. 2012. Implication of AMP-activated protein kinase in transient receptor potential vanilloid type 1-mediated activation of endothelial nitric oxide synthase. Mol Med doi: 10.2119/molmed.2011.00461.
9. Chiou, W.F., Chou, C.J., Shum, A.Y. and Chen, C.F. 1992. The vasorelaxant effect of evodiamine in rat isolated mesenteric arteries: mode of action. Eur J Pharmacol 215, 277-283.
10. Chiou, W.F., Sung, Y.J., Liao, J.F., Shum, A.Y. and Chen, C.F. 1997. Inhibitory effect of dehydroevodiamine and evodiamine on nitric oxide production in cultured murine macrophages. J Nat Prod 60, 708-711.
11. De Petrocellis, L., Orlando, P., Moriello, A.S., Aviello, G., Stott, C., Izzo, A.A. and Di Marzo, V. 2012. Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation. Acta Physiol (Oxf) 204, 255-266.
12. Dutta, A. and Deshpande, S.B. 2010. Cardio-respiratory reflexes evoked by phenylbiguanide in rats involve vagal afferents which are not sensitive to capsaicin. Acta Physiol (Oxf) 200, 87-95.
13. Franchini, M. and Montagnana, M. 2011. Low-density lipoprotein receptor-related protein 1: new functions for an old molecule. Clin Chem Lab Med 49, 967-970.
14. Giannoglou, G.D., Chatzizisis, Y.S., Zamboulis, C., Parcharidis, G.E., Mikhailidis, D.P. and Louridas, G.E. 2008. Elevated heart rate and atherosclerosis: an overview of the pathogenetic mechanisms. Int J Cardiol 126, 302-312.
15. Glass, C.K. and Witztum, J.L. 2001. Atherosclerosis: the road ahead. Cell 104, 503-516.
16. Hansson, G.K. and Hermansson, A. 2011. The immune system in atherosclerosis. Nat Immunol 12, 204-212.
17. Holzer, P. 2011. Acid sensing by visceral afferent neurones. Acta Physiol (Oxf) 201, 63-75.
18. Hu, Y., Fahmy, H., Zjawiony, J.K. and Davies, G.E. 2010. Inhibitory effect and transcriptional impact of berberine and evodiamine on human white preadipocyte differentiation. Fitoterapia 81, 259-268.
19. Kobayashi, Y. 2003. The nociceptive and anti-nociceptive effects of evodiamine from fruits of Evodia rutaecarpa in mice. Planta Med 69, 425-428.
20. Kobayashi, Y., Nakano, Y., Hoshikuma, K., Yokoo, Y. and Kamiya, T. 2000. The bronchoconstrictive action of evodiamine, an indoloquinazoline alkaloid isolated from the fruits of Evodia rutaecarpa, on guinea-pig isolated bronchus: possible involvement on vanilloid receptors. Planta Med 66, 526-530.
21. Kobayashi, Y., Hoshikuma, K., Nakano, Y., Yokoo, Y. and Kamiya, T. 2001a. The positive inotropic and chronotropic effects of evodiamine and rutaecarpine, indoloquinazoline alkaloids isolated from the fruits of Evodia rutaecarpa, on the guinea-pig isolated right atria: possible involvement of vanilloid receptors. Planta Med 67, 244-248.
22. Kobayashi, Y., Nakano, Y., Kizaki, M., Hoshikuma, K., Yokoo, Y. and Kamiya, T. 2001b. Capsaicin-like anti-obese activities of evodiamine from fruits of Evodia rutaecarpa, a vanilloid receptor agonist. Planta Med 67, 628-633.
23. Lee, T.S., Shiao, M.S., Pan, C.C. and Chau, L.Y. 1999. Iron-deficient diet reduces atherosclerotic lesions in apoE-deficient mice. Circulation 99, 1222-1229.
24. Lehmann, J.M., Kliewer, S.A., Moore, L.B., Smith-Oliver, T.A., Oliver, B.B., Su, J.L., Sundseth, S.S., Winegar, D.A., Blanchard, D.E., Spencer, T.A. and Willson, T.M. 1997. Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. J Biol Chem 272, 3137-3140.
25. Li, L., Chen, J., Ni, Y., Feng, X., Zhao, Z., Wang, P., Sun, J., Yu, H., Yan, Z., Liu, D., Nilius, B. and Zhu, Z. 2012. TRPV1 activation prevents nonalcoholic fatty liver through UCP2 upregulation in mice. Pflugers Arch 463, 727-732.
26. Liao, C.H., Pan, S.L., Guh, J.H., Chang, Y.L., Pai, H.C., Lin, C.H. and Teng, C.M. 2005. Antitumor mechanism of evodiamine, a constituent from Chinese herb Evodiae fructus, in human multiple-drug resistant breast cancer NCI/ADR-RES cells in vitro and in vivo. Carcinogenesis 26, 968-975.
27. Libby, P., Aikawa, M. and Schönbeck, U. 2000. Cholesterol and atherosclerosis. Biochim Biophys Acta 1529, 299-309.
28. Liu, Y.N., Pan, S.L., Liao, C.H., Huang, D.Y., Guh, J.H., Peng, C.Y., Chang, Y.L. and Teng, C.M. 2009. Evodiamine represses hypoxia-induced inflammatory proteins expression and hypoxia-inducible factor 1alpha accumulation in RAW264.7. Shock, 32, 263-269.
29. Ma, L., Zhong, J., Zhao, Z., Luo, Z., Ma, S., Sun, J., He, H., Zhu, T., Liu, D., Zhu, Z. and Tepel, M. 2011. Activation of TRPV1 reduces vascular lipid accumulation and attenuates atherosclerosis. Cardiovasc Res 92, 504-513.
30. Miller, D.T., Ridker, P.M., Libby, P. and Kwiatkowski, D.J. 2007. Atherosclerosis: the path from genomics to therapeutics. J Am Coll Cardiol 49, 1589-1599.
31. Miyake, J.H., Duong-Polk, X.T., Taylor, J.M., Du, E.Z., Castellani, L.W., Lusis, A.J. and Davis, R.A. 2002. Transgenic expression of cholesterol-7-α-hydroxylase prevents atherosclerosis in C57BL/6J mice. Arterioscler Thromb Vasc Biol 22, 121-126.
32. Nakashima, Y., Plump, A.S., Raines, E.W., Breslow, J.L. and Ross, R. 1994. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb 14, 133-140.
33. Ozaki, K., Kubo, T., Imaki, R., Shinagawa, H., Fukaya, H., Ohtaki, K., Ozaki, S., Izumi, T. and Aizawa, Y. 2006. The anti-atherosclerotic effects of lipid lowering with atorvastatin in patients with hypercholesterolemia. J Atheroscler Thromb 13, 216-219.
34. Pearce, L.V., Petukhov, P.A., Szabo, T., Kedei, N., Bizik, F., Kozikowski, A.P. and Blumberg, P.M. 2004. Evodiamine functions as an agonist for the vanilloid receptor TRPV1. Org Biomol Chem 2, 2281-2286.
35. Peet, D.J., Turley, S.D., Ma, W., Janowski, B.A., Lobaccaro, J.M., Hammer, R.E. and Mangelsdorf, D.J. 1998. Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha. Cell 93, 693-704.
36. Rang, W.Q., Du, Y.H., Hu, C.P., Ye, F., Tan, G.S., Deng, H.W. and Li, Y.J. 2003. Protective effects of calcitonin gene-related peptide-mediated evodiamine on guinea-pig cardiac anaphylaxis. Naunyn Schmiedebergs Arch Pharmacol 367, 306-311.
37. Rang, W.Q., Du, Y.H., Hu, C.P., Ye, F., Xu, K.P., Peng, J., Deng, H.W. and Li, Y.J. 2004. Protective effects of evodiamine on myocardial ischemia-reperfusion injury in rats. Planta Med 70, 1140-1143.
38. Reddick, R.L., Zhang, S.H. and Maeda, N. 1994. Atherosclerosis in mice lacking apo E. Evaluation of lesional development and progression. Arterioscler Thromb 14, 141-147.
39. Repa, J.J., Berge, K.E., Pomajzl, C., Richardson, J.A., Hobbs, H. and Mangelsdorf, D.J. 2002. Regulation of ATP-binding cassette sterol transporters ABCG5 and ABCG8 by the liver X receptors alpha and beta. J Biol Chem 277, 18793-18800.
40. Shi, J., Yan, J., Lei, Q., Zhao, J., Chen, K., Yang, D., Zhao, X. and Zhang, Y. 2009. Intragastric administration of evodiamine suppresses NPY and AgRP gene expression in the hypothalamus and decreases food intake in rats. Brain Res 1247, 71-78.
41. Shin, S.K., Ha, T.Y., McGregor, R.A. and Choi, M.S. 2011. Long-term curcumin administration protects against atherosclerosis via hepatic regulation of lipoprotein cholesterol metabolism. Mol Nutr Food Res 55, 1829-1840.
42. Shoji, N., Umeyama, A., Takemoto, T., Kajiwara, A. and Ohizumi, Y. 1986. Isolation of evodiamine, a powerful cardiotonic principle, from Evodia rutaecarpa Bentham (Rutaceae). J Pharm Sci 75, 612-613.
43. Takada, Y., Kobayashi, Y. and Aggarwal, B.B. 2005. Evodiamine abolishes constitutive and inducible NF-kappaB activation by inhibiting IkappaBalpha kinase activation, thereby suppressing NF-kappaB-regulated antiapoptotic and metastatic gene expression, up-regulating apoptosis, and inhibiting invasion. J Biol Chem 280, 17203-17212.
44. Trigatti, B.L., Krieger, M. and Rigotti, A. 2003. Influence of the HDL receptor SR-BI on lipoprotein metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 23, 1732-1738.
45. Tsai, J.Y., Su, K.H., Shyue, S.K., Kou, Y.R., Yu, Y.B., Hsiao, S.H., Chiang, A.N., Wu, Y.L., Ching, L.C. and Lee, T.S. 2010. EGb761 ameliorates the formation of foam cells by regulating the expression of SR-A and ABCA1: role of haem oxygenase-1. Cardiovasc Res 88, 415-423.
46. Ulven, S.M., Dalen, K.T., Gustafsson, J.A. and Nebb, H.I. 2005. LXR is crucial in lipid metabolism. Prostaglandins Leukot Essent Fatty Acids 73, 59-63.
47. Wang, T., Wang, Y., Kontani, Y., Kobayashi, Y., Sato, Y., Mori, N. and Yamashita, H. 2008. Evodiamine improves diet-induced obesity in a uncoupling protein-1-independent manner: involvement of antiadipogenic mechanism and extracellularly regulated kinase/mitogen-activated protein kinase signaling. Endocrinology 149, 358-366.
48. Wang, T., Wang, Y. and Yamashita, H. 2009. Evodiamine inhibits adipogenesis via the EGFR-PKCalpha-ERK signaling pathway. FEBS Lett 583, 3655-3659.
49. Weber, C. and Noels, H. 2011. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med 17, 1410-1422.
50. Wittenburg, H. and Carey, M.C. 2002. Biliary cholesterol secretion by the twinned sterol half-transporters ABCG5 and ABCG8. J Clin Invest 110, 605-609.
51. Yamahara, J., Yamada, T., Kitani, T., Naitoh, Y. and Fujimura, H. 1989. Antianoxic action of evodiamine, an alkaloid in Evodia rutaecarpa fruit. J Ethnopharmacol 27, 185-192.
52. Yang, D., Luo, Z., Ma, S., Wong, W.T., Ma, L., Zhong, J., He, H., Zhao, Z., Cao, T., Yan, Z., Liu, D., Arendshorst, W.J., Huang, Y., Tepel, M. and Zhu, Z. 2010. Activation of TRPV1 by dietary capsaicin improves endothelium-dependent vasorelaxation and prevents hypertension. Cell Metab 12, 130-141.
53. Yoshizumi, M., Houchi, H., Ishimura, Y., Hirose, M., Kitagawa, T., Tsuchiya, K., Minakuchi, K. and Tamaki, T. 1997. Effect of evodiamine on catecholamine secretion from bovine adrenal medulla. J Med Invest 44, 79-82.
54. Yu, S.Q. and Wang, D.H. 2011. Intrathecal injection of TRPV1 shRNA leads to increases in blood pressure in rats. Acta Physiol (Oxf) 203, 139-147.
55. Yu, L., Li-Hawkins, J., Hammer, R.E., Berge, K.E., Horton, J.D., Cohen, J.C. and Hobbs, H.H. 2002. Overexpression of ABCG5 and ABCG8 promotes biliary cholesterol secretion and reduces fractional absorption of dietary cholesterol. J Clin Invest 110, 671-680.
56. Yu, L., York, J., von Bergmann, K., Lutjohann, D., Cohen, J.C. and Hobbs, H.H. 2003. Stimulation of cholesterol excretion by the liver X receptor agonist requires ATP-binding cassette transporters G5 and G8. J Biol Chem 78, 15565-15570.
57. Zhang, L.L., Yan, L.D., Ma, L.Q., Luo, Z.D., Cao, T.B., Zhong, J., Yan, Z.C., Wang, L.J., Zhao, Z.G., Zhu, S.J., Schrader, M., Thilo, F., Zhu, Z.M. and Tepel, M. 2007. Activation of transient receptor potential vanilloid type-1 channel prevents adipogenesis and obesity. Circ Res 100, 1063-1070.
58. Zhao, J.F., Ching, L.C., Huang, Y.C., Chen, C.Y., Chiang, A.N., Kou, Y.R., Shyue, S.K. and Lee, T.S. 2012. Molecular mechanism of curcumin on the suppression of cholesterol accumulation in macrophage foam cells and atherosclerosis. Mol Nutr Food Res 56, 691-701.